High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma

Biomedical Chromatography

Volumn 24, Issue 7, 2010, Pages 789-793

  Miura, Masatomo ^a   Takahashi, Naoto ^b   Sawada, Ken Ichi ^b  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dasatinib; HPLC; Human plasma; Nilotinib

Indexed keywords

AMINO ACIDS; EXTRACTION; FLOW RATE; OPTICAL DATA PROCESSING; PHASE SEPARATION; PLASMA (HUMAN);

DASATINIB; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMAS; LINEAR RANGE; NILOTINIB; QUANTITATIVE DETERMINATIONS; SIMPLE++; SOLID-PHASE EXTRACTION; ULTRA VIOLET DETECTION; ULTRAVIOLET DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILE; DASATINIB; IMATINIB; METHANOL; NILOTINIB;

ARTICLE; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION;

EID: 77953487268     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1364     Document Type: Article

References (8)

1. De Francia S, D'Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di Carlo F and Di Perri G. New HPLC-MS method for the simultaneous quantifi cation of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of Chromatography B: Biomedical Sciences and Applications 2009; 877: 1721-1726.
2. Deremer DL, Ustun C and Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics 2008; 30: 1956-1975.
3. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N and Decosterd LA. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 2009; 877: 1982-1996.
4. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I and Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-4028.
5. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiff ers J, Begaud B, Moore N, Molimard M and Mahon FX. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499.
6. Pursche S, Ottmann OG, Ehninger G and Schleyer E. High-performance liquid chromatography method with ultraviolet detection for the quantifi cation of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. Journal of Chromatography B: Biomedical Sciences and Applications 2007; 852: 208-216.
7. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
8. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG and Griffi n JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129-141. (Pubitemid 40248339)